

Cancer-Selective Targeting of the NF- κ B Survival Pathway with GADD45 β /MKK7 Inhibitors

Laura Tornatore, Annamaria Sandomenico, Domenico Raimondo, Caroline Low, Alberto Rocci, Cathy Tralau-Stewart, Daria Capece, Daniel D'Andrea, Marco Bua, Eileen Boyle, Mark van Duin, Pietro Zoppoli, Albert Jaxa-Chamiec, Anil K. Thotakura, Julian Dyson, Brian A. Walker, Antonio Leonardi, Angela Chambery, Christoph Driessen, Pieter Sonneveld, Gareth Morgan, Antonio Palumbo, Anna Tramontano, Amin Rahemtulla, Menotti Ruvo,* and Guido Franzoso*

*Correspondence: menotti.ruvo@unina.it (M.R.), g.franzoso@imperial.ac.uk (G.F.)
<http://dx.doi.org/10.1016/j.ccell.2014.11.021>

(Cancer Cell 26, 495–508; October 13, 2014)

Following publication of this manuscript, the authors discovered some panels that had been incorrectly cropped in Figures S4H and S5V in the Supplemental Information.

As a result of this error, the 0 hr time points of the top PARP-1 panel of Figure S4H, U266, the Tot-JNK and Tot-ERK panels of Figure S5V, U266, and the P-p38 panel of Figure S5V, RPMI-8226, as well as the 0 hr and 0.5 hr, DTP3, time points of the P-ERK panel of Figure S5V, RPMI-8226, were accidentally omitted from these panels. An extra time point (i.e., a 1.5 hr time point, T/I) was also accidentally included in the P-ERK panel of this figure. Due to an analogous error, the P-JNK panel of Figure S5V, RPMI-8226, was incorrectly aligned.

The authors also discovered an antibody that had been erroneously omitted from the Supplemental Experimental Procedures. This antibody, anti-PARP-1 (9532S; 1:1,000), should have been included in the section “Antibodies, Reagents and Western Blots.”

A corrected version of the Supplemental Information is now available online.

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

Miranda L. Broz, Mikhail Binnewies, Bijan Boldajipour, Amanda E. Nelson, Joshua L. Pollack, David J. Erle, Andrea Barczak, Michael D. Rosenblum, Adil Daud, Diane L. Barber, Sebastian Amigorena, Laura J. van't Veer, Anne I. Sperling, Denise M. Wolf, and Matthew F. Krummel*

*Correspondence: matthew.krummel@ucsf.edu
<http://dx.doi.org/10.1016/j.ccell.2014.11.010>

(Cancer Cell 26, 638–652; November 10, 2014)

FLT3L and FLT3 were erroneously written as FTL3L and FTL3 at multiple points in the text. Only FLT3L (FMS-like tyrosine kinase ligand) and FLT3 (FMS-like tyrosine kinase) are discussed in this paper. These errors have been corrected online.